Ernst-Günter Afting

Ernst-Günter Afting currently works at Olympus Europa GmbH, as Director, BioMedCredit AG, as Member-Supervisory Board from 2012, and Olympus Europa Holding GmbH, as Member-Supervisory Board.
Dr. Afting also formerly worked at Hoechst AG, as Chairman & CEO-Pharmaceutical Division in 1993, Roussel Uclaf SA, as President & Chief Executive Officer from 1993 to 1995, GSF-National Research Center for Environment & Health GmbH, as President & Chief Executive Officer from 1995 to 2006, Intercell AG, as Vice Chairman-Supervisory Board from 2012 to 2013, Avontec GmbH, as Chairman-Supervisory Board in 2010, Biovertis AG, as Chairman-Supervisory Board, Quidel Corp., as Director, Titan Pharmaceuticals, Inc., as Director, Sequenom, Inc., as Independent Director from 2012 to 2014, Quikbyte Software, Inc., as Director, Behringwerke AG, as Director in 1989, Enanta Pharmaceuticals, Inc., as Independent Class III Director from 2012 to 2017, Sorrento Therapeutics, Inc., as Independent Director from 2013 to 2014, and Retrotope, Inc., as Director.
Dr. Afting received his graduate degree and doctorate degree from the University of Freiburg and undergraduate degree from the University of Münster.